

08 December 2022

Head/Neck and Urothelial cancer

Information as available from RISOH (regional information system Oncology & Heamatology) Aug – Oct 2022

1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:

- Carboplatin (monotherapy or in combination with 5-FU) : 14
- Cisplatin (monotherapy or in combination with 5-FU) : 16
- Cetuximab with/without chemotherapy : <5
- Cetuximab with radiotherapy : <5
- Pembrolizumab monotherapy : 7
- Pembrolizumab with chemotherapy : <5
- Nivolumab : 6
- Docetaxel (monotherapy or in combination with 5-FU) : <5
- Fluorouracil (5FU) : <5
- **Radiotherapy only**
- Total No. H&N patients actively undergoing radiotherapy alone during 3 month period (Aug - Oct) - 71
 - Radical radiotherapy alone – 55
 - Palliative radiotherapy alone – 16
- Other: **Gemcitabine** : <5

2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:

- Total number of head and neck cancer patients : 47
- **Please Note the following is not available from a RISOH query field:**
- Number of locally advanced head and neck cancer patients
- Number of unresectable recurrent and/or metastatic head and neck cancer patients

3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents:

- Avelumab : <5
- Atezolizumab : <5
- Carboplatin with Gemcitabine : <5
- Carboplatin single or in any other combination : <5
- Cisplatin with Gemcitabine : <5
- Cisplatin single or in any other combination : <5
- Nivolumab : <5
- Pembrolizumab : <5
- Any other regimen including Paclitaxel : <5

08 December 2022

- Any other chemotherapy regimen : <5
- Other active systemic anti-cancer therapy [please state] : <5
- Palliative care only – **Not available in RISOH query field**

4. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Head and Neck Cancer Clinical Trials Open to Recruitment in Belfast HSC Trust

Trial Name		Patients Recruited
COMPARE	Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer	<5
CCS1477-01	An open-label phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumours. Although not specific to H&N, one head and neck cancer patient has been recruited to this early phase study.	19 (1 H&N patient)

Head and Neck Cancer Clinical Trials in Set-up

PETNECK 2	PET-CT guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head and neck cancer
ADePT-DDR	Accelerating the Development and implementation of Personalised Treatments of DNA Damage Response agents and radiotherapy +/- immunotherapy for head and neck squamous cell cancer
BAYER 21343	An open-label, phase Ib, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor Inhibitor (AhRi) Bay 2416964 in combination with Pembrolizumab in participants with advanced solid tumours.

08 December 2022

5. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Urothelial Cancer Clinical Trials Open to Recruitment in Belfast HSC Trust

Trial Name		Patients Recruited
MK3475-045 & MK3475-587	MK3475-045: A Phase III Randomised Clinical Trial of MK-3475 versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer.	MK3475-045: <5 Now closed to recruitment
	MK3475-587: A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial (MK475-04)	MK3475-587: <5
IMvigor011	A Phase III, double-blind, multicenter, randomized study of Atezolizumab (anti-PDL1 antibody) versus placebo as adjuvant therapy in patients with high-risk muscle-invasive bladder cancer who are circulating tumour DNA (ctDNA) positive following cystectomy.	Opened to recruitment but had to be halted due to regulatory issues specific to NI

Urothelial Cancer Clinical Trials in Set-up

RE-ARM	A Randomised phase II trial of Enhancement of efficacy of Atezolizumab by Radiotherapy in Metastatic urothelial carcinoma
---------------	---

Please note:

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.